Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: quidditch who wrote (6236)	1/9/2005 9:14:46 AM
From: Harold Engstrom	Read Replies (1) \| Respond to of 10345

Hello from Belgium, where the keyboards are arranged to frustrate the unsavvy american typist! 8K patients would be almost US200M runrate for 2005 - and this is after only 1 month on the market. I think we will see many more revenue upgrqdes like that of 1st Albany. H

To: quidditch who wrote (6236)	1/15/2005 11:13:59 PM
From: rkrw	Read Replies (2) \| Respond to of 10345

MS message board post......... MS Physician Consulting Conference Call, Tysabri doing well --------------------------------------------------- a few quick notes From the S.G. Cowen Multiple Sclerosis Physician Consulting Conference Call Some comments from Dr. Ellen Lathi, MD, member of the team at the MS Center at St. Elizabeth’s Medical Center, Tufts University School of Medicine, Brighton, Massachusetts. In this center they have already already infused about 50 patients. Some already on their 2nd dose. They are going to infuse another 10-15 between now and next Tuesday. She heard that in a very large MS center in the South they are going to have 1000 or more patients on Tysabri, The infusion process going extremely well, no big reactions. So mild that the patients wondering if they are gettting the drug or just water. "Everyone wants Tysabri, people are chomping at the bit for it because of the convenience, because of the once-a-month. They know there is not the flu-like symptoms. Even our people who don't have much flu-like symptoms think that they lose part of a day from the fatigue after the interferon. So people really want it. So I think most newly diagnosed patients are opting for it." *** all three MS physicians on the conference call expect that about half of their patients will be on Tysabri after a year.